Showing results (411-420 of 1,039) with videos related to
Sort By:
Pageof 104
Circulation|May 22, 2002
Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) ProjectMarc A Pfeffer, Anthony Keech, Frank M Sacks, et al.Circulation|July 2, 2015
Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of SpironolactoneAmil M Shah, Brian Claggett, Nancy K Sweitzer, et al.Clinical Trials (London, England)|April 1, 2025
Aspirin in primary prevention: Undue reliance on an uninformative trial led to misinformed clinical guidelinesJanet Wittes, David L DeMets, KyungMann Kim, et al.Circulation|June 26, 2002
Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research studyGary F Mitchell, Joseph L Izzo, Yves Lacourcière, et al.American Heart Journal|June 7, 2011
Incremental value of echocardiographic assessment beyond clinical evaluation for prediction of death and development of heart failure after high-risk myocardial infarctionAnil Verma, Marc A Pfeffer, Hicham Skali, et al.The American Journal of Cardiology|September 5, 2006
Evaluation of the National Cholesterol Education Program Adult Treatment Panel III algorithm for selecting candidates for statin therapy: insights from the A to Z trialJames A de Lemos, Stephen D Wiviott, Sabina A Murphy, et al.Journal of the American College of Cardiology|May 16, 2006
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programLars G Olsson, Karl Swedberg, Anique Ducharme, et al.Circulation. Cardiovascular Quality and Outcomes|March 18, 2010
Cognitive function and anticoagulation control in patients with atrial fibrillationGreg C Flaker, Janice Pogue, Salim Yusuf, et al.Lancet (London, England)|December 13, 2005
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trialBradi B Granger, Karl Swedberg, Inger Ekman, et al.European Journal of Heart Failure|September 6, 2017
Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortalityElke Platz, Pardeep S Jhund, Brian L Claggett, et al.Pageof 104